Mark Cuban has a message for America's healthcare industry, and it's not subtle: you're too big, too profitable, and too indifferent to the people you're supposed to serve.

The billionaire entrepreneur and founder of online pharmacy Cost Plus Drugs is escalating his criticism of the U.S. healthcare system, particularly taking aim at high-deductible insurance plans that he says are bleeding patients dry while enriching executives.

The Deductible Trap

"This is your reminder that all those people who had to switch to lower premium, higher deductible plans, will now be paying full retail price on their brand and specialty drugs for LONGER," Cuban posted on X this week. "Their deductibles went up, costing them thousands of dollars a year more."

It's not just about individual pain points. Cuban estimates that in aggregate, "patients may be paying billions of dollars more" due to these plan changes.

Here's where it gets particularly galling. Under Affordable Care Act plans, the rebates from drugs purchased before deductibles are met often flow to pharmacy benefit managers owned by the same insurance companies selling the plans. For employer-sponsored coverage, the situation is even worse.

"If your deductible went up, and it probably did, the in-deductible rebates are going right to your company's and the PBM's bank account," Cuban explained.

His punchline cuts deep: "The bigger your deductible, the sicker you are, the more that goes to your CEO's balance sheet."

Cuban's conclusion? "It's time to change healthcare. These healthcare companies are too big to care."

A System Built on Billing Errors

This isn't Cuban's first rodeo criticizing healthcare's broken incentives. Just before Christmas, he argued that overbilling, care denials, and misleading cost estimates have become business as usual.

"If we fined insurers and providers $100 every time they over-billed, incorrectly denied care or misrepresented any amount of patient out of pocket, we could pay off the national debt," he wrote on X.

His prescription for reform is radical but clear: "Break them up. Make them divest non-insurance companies," he wrote. "And when we are done with the insurance companies, we go to the hospitals and then to the pharma wholesalers. Break 'em up. Make the markets efficient again."

Can Patients Really Shop Around?

Some skeptics argue that expecting patients to comparison-shop for healthcare in such a deliberately opaque system is unrealistic. Cuban pushed back, pointing to his own experience running Cost Plus Drugs.

"It happens already. I email and talk to people who buy from Cost Plus all the time," Cuban replied. "I pay deductibles for people all the time. I help people get their [prior authorizations] overturned. All the time. The hardest part is having them count against their deductible."

That last bit is telling. Even when Cuban personally intervenes to help patients navigate the system, the bureaucratic machinery makes it difficult to ensure those expenses count toward their coverage.

Cuban's broader point extends beyond healthcare. He's highlighting how powerful, consolidated systems often reward insiders while shutting out everyone else. It's the same dynamic that kept regular investors locked out of venture capital opportunities for decades, limited to investing only after companies went public and the biggest gains were already captured by institutional players.

Whether through Cost Plus Drugs or his public advocacy, Cuban is betting that transparency and competition can crack open industries that have grown comfortable with their gatekeeping power. The healthcare giants may be too big to care, as he puts it, but they might not be too big to challenge.